Cyclopentadienyl anions ([Cp]) are pervasive ligands in coordination chemistry. In contrast, heavy-element derivatives of these ligands, particularly those that feature arsenic, are not as well developed. In this work, a new arsenic-based heterocycle with a structure analogous to [Cp] is presented. Reaction of KAs with benzyl azide (BnN) leads to fragmentation of the [As] core and C-H activation of two [BnN] units to give the five-membered arsenic heterocycle [As(NC(Ph))]. This arsenic heterocycle was studied by nuclear magnetic resonance and UV-vis spectroscopy, X-ray diffraction, and its electronic structure was investigated computationally.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734114 | PMC |
| http://dx.doi.org/10.1021/acs.organomet.4c00476 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and Characterization of a 1,2,4-Diazarsolide Anion.
Organometallics
January 2025
Department of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, United Kingdom.
Cyclopentadienyl anions ([Cp]) are pervasive ligands in coordination chemistry. In contrast, heavy-element derivatives of these ligands, particularly those that feature arsenic, are not as well developed. In this work, a new arsenic-based heterocycle with a structure analogous to [Cp] is presented.
View Article and Find Full Text PDFFirst case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acid.
Hematology
December 2024
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Article Synopsis
- - Variant acute promyelocytic leukemia (vAPL) is a specific type of APL that involves atypical fusion proteins, which are difficult to identify using standard methods like PCR and FISH, necessitating newer techniques like next-gen sequencing.
- - Patients with vAPL often show resistance to traditional treatments like arsenic trioxide and all trans-retinoic acid, leading to ambiguous prognoses, but venetoclax (VEN) has demonstrated effectiveness when combined with ATRA.
- - This research presents the first recorded case of vAPL with a TFG-RARA fusion gene successfully treated with VEN and ATRA, achieving complete remission, suggesting that VEN could improve outcomes for vAPL patients.
Synthesis and Antitumour Activity of Hybrid Compounds Based on 4-Aminophenylarsonic Acid and Spatially Hindered Phenols.
Dokl Biochem Biophys
December 2024
Arbuzov Institute of Organic and Physical Chemistry, Kazan Scientific Center of the Russian Academy of Sciences, Kazan, Russia.
One of the main modern approaches to the creation of effective drugs is the design of new biologically active substances containing two or more pharmacophore groups in their structure. In recent years, there have been many publications on the synthesis and study of biological activity, including antitumour activity, of new organo-arsenic compounds. It is known that spatially hindered phenols can also have antitumor activity, so the synthesis and study of hybrid compounds based on organo-arsenic compounds and spatially hindered phenols is a relevant area of research.
View Article and Find Full Text PDFEffects of imidazole derivatives on cellular proliferation and apoptosis in myeloid leukemia.
BMC Cancer
September 2024
Department of Biomedicine, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Article Synopsis
- Acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) are types of leukemia that present unique challenges due to drug resistance and the presence of leukemia stem cells (LSC), necessitating the search for new therapies.
- Four novel imidazole derivatives were tested, revealing that they effectively inhibited the proliferation of APL (NB4) and CML (K562) cell lines by inducing apoptosis and downregulating key signaling pathways.
- The study suggested that combining the imidazole derivatives with standard treatments like ATRA and Imatinib could enhance the anti-leukemic effects by further targeting Wnt/beta-catenin pathway genes.
Successfully treatment of PLZF-RARα positive acute promyelocytic leukemia by Venetoclax combining with decitabine: a case report and literature review.
Hematology
December 2024
Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
Introduction: Acute promyelocytic leukemia (APL) is mainly due to the chromosome translocation (15; 17) (q22; q12), leading to the formation of PML-RARα fusion protein. However, some patients carried rare translocation involving RARα gene, and they were referred to as variant APL caused by the RAR family (RARα, RARB, and RARG) and partner genes. PLZF-RARα was a rare type of molecular genetic abnormality with unfavorable prognosis that has been reported in few cases in variant APL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!